Cationic base modifications on oligophosphates neutralize negative charge, reducing background noise in nanopore sequencing.
A metabolomics analysis system determines metabolic age using specific biomarker levels.
Isolated polypeptides stimulate CD4 and CD8 T cell activation to overcome viral antagonism of endogenous anti-viral proteins.
Heteroaryl inhibitors bind the myristoyl pocket to block ATP access, overcoming resistance in mutant Bcr-Abl forms.
Nucleic acid molecules encoding grg8 polypeptides transform organisms to withstand toxic herbicide levels.
Suppresses p21-mediated apoptosis inhibition using RNA interference, enabling effective p53-directed tumor cell death.
Water-soluble ligands and recyclable palladium catalysts synthesize xylose derivatives in aqueous media, reducing organic solvent waste.
Luciola italica luciferase mutants shift bioluminescence emission to red wavelengths via amino acid substitutions.
A ClorDNA virus promoter drives gene expression in algal cells to enable efficient genetic transformation.
Multimeric FcγRIIa polypeptides increase selectivity for immune complexes, reducing the dose required for effective inflammation inhibition.
Novel amphiphilic compounds stabilize membrane proteins against denaturation, enabling high-quality crystal formation for structural determination.
Targeting integration sites with extended methylation-free CpG islands prevents epigenetic silencing and ensures stable high-level protein expression.
Fluorescent proteins link gene expression levels to selectable markers, resolving heterogeneous cell population issues.
GCC technology maps three-dimensional chromatin arrangement using cross-linking and parallel sequencing.
Nucleotide sugar and backbone modifications increase guide RNA resistance to degradation while maintaining target binding affinity in eukaryotic cells.
Targeted genome mutations in recombinant chimeric flaviviruses reduce viscerotropism while maintaining immunogenicity.
Modified Fc regions reduce immunogenicity while sustaining anti-tumor immunity against cancer cells.
Optimized siRNAs target mutated CLCN7 mRNA transcripts to reduce protein expression while sparing wild-type sequences.
Compounds bind gp130 to block IL-6 signaling, addressing insufficient inhibitor potency in cancer treatment.
Incorporating unnatural nucleotides with reactive linkers into oligonucleotides via enzymatic replication.